Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre

European Urology

Volumn 49, Issue 3, 2006, Pages 519-527

  Kalsi, Vinay ^a   Popat, Roshni B ^a   Apostolidis, Apostolos ^a   Kavia, Rajesh ^a   Odeyemi, Isaac A O ^b   Dakin, Helen A ^c   Warner, Juliet ^c   Elneil, Soheir ^a   Fowler, Clare J ^a   Dasgupta, Prokar ^a,d  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b ALLERGAN PLC   (United States)

^c Decision Resources Group   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

BoNT A; Botox; Botulinum toxin A; Cost effectiveness; Detrusor overactivity; Idiopathic detrusor overactivity; Neurogenic detrusor overactivity; Urinary urge incontinence

Indexed keywords

BOTULINUM TOXIN A; TRIMETHOPRIM;

ARTICLE; BLADDER DYSFUNCTION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYSTOMETRY; DETRUSOR MUSCLE; FOLLOW UP; HUMAN; INCONTINENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MICTURITION; MULTIPLE SCLEROSIS; MYELITIS; NEUROGENIC BLADDER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPASTIC PARAPLEGIA; SPINA BIFIDA; SPINAL CORD INJURY; UNITED KINGDOM; URODYNAMICS;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEUROMUSCULAR AGENTS; URINARY INCONTINENCE;

EID: 32944460290     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.11.006     Document Type: Article

References (26)

1. A. Giannantoni, S.M. Di Stasi, R.L. Stephen, V. Bini, E. Costantini, and M. Porena Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study J Urol 172 2004 240 243
2. B. Schurch, M. de Seze, P. Denys, E. Chartier-Kastler, F. Haab, and K. Everaert Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study J Urol 174 2005 196 200
3. A. Reitz, M. Stohrer, G. Kramer, G. Del Popolo, E. Chartier-Kastler, and J. Pannek European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity Eur Urol 45 2004 510 515
4. C.P. Smith, J. Nishiguchi, M. O'Leary, N. Yoshimura, and M.B. Chancellor Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra Urology 65 2005 37 41
5. J. Grosse, G. Kramer, and M. Stohrer Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence Eur Urol 47 2005 653 659
6. S. Hajebrahimi, W. Altaweel, J. Cadoret, E. Cohen, and J. Corcos Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results Can J Urol 12 2005 2543 2546
7. D.E. Rapp, A. Lucioni, E.E. Katz, R.C. O'Connor, G.S. Gerber, and G.T. Bales Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience Urology 63 2004 1071 1075
8. H.C. Kuo Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents Urology 63 2004 868 872
9. M.K. Flynn, G.D. Webster, and C.L. Amundsen The effect of botulinum-a toxin on patients with severe urge urinary incontinence J Urol 172 2004 2316 2320
10. M.B. Chancellor, and C.P. Smith One surgeon's experience in 50 patients with botulinum toxin injection into the bladder and urethra (Abstract) J Urol 167 2002 249
11. B. Schurch, A. Reitz, and G. Tenti Electromotive drug administration of lidocaine to anesthetize the bladder before botulinum-A toxin injections into the detrusor Spinal Cord 42 2004 338 341
12. R. Popat, A. Apostolidis, V. Kalsi, G. Gonzales, C.J. Fowler, and P. Dasgupta A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin J Urol 174 2005 984 989
13. Werner M, Schmid D, Schurch B, Schuessler B. Efficacy of botulinum-A toxin in the treatment of refractory overactive bladder syndrome: preliminary results of a prospective non-randomized study. Non-discussion paper presented at the 2004 International Continence Society Congress, Paris 2004.
14. M. Harper, R.B. Popat, R. Dasgupta, C.J. Fowler, and P. Dasgupta A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity BJU Int 92 2003 325 326
15. P. Abrams, L. Cardozo, M. Fall, D. Griffiths, P. Rosier, and U. Ulmsten The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
16. B. Schurch, M. Stohrer, G. Kramer, D.M. Schmid, G. Gaul, and D. Hauri Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol 164 2000 692 769
17. E.S. Rovner, and A.J. Wein Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin BJU Int 86 Suppl 2 2000 44 53 discussion 53-54
18. R. Dmochowski Treatment of the overactive bladder: Where we stand in 2003 Rev in Urol 5 2003 S11
19. Swinscow TDV, Revised by Campbell MJ. Survival analysis. In: Statistics at Square One. Ninth ed. London: BMJ Publishing Group (http://bmj.bmjjournals. com/collections/statsbk/index.shtml), 1997.
20. National Institute for Clinical Excellence Guide to the methods of technology appraisal 2004 April NICE London
21. D.J. Torgerson, and J. Raftery Economic notes. Discounting BMJ 319 1999 914 915
22. N. Devlin, and D. Parkin Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 13 2004 437 452
23. B.J. O'Brien, R. Goeree, L. Bernard, A. Rosner, and T. Williamson Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective Clin Ther 23 2001 2038 2049
24. L. Curtis, and A. Netten Unit Costs of Health and Social Care 2004 2004 PSSRU Personal Social Services Research Unit Canterbury, UK
25. Department of Health. NHS Reference costs Appendix 1 NHS trusts (http://www.dh.gov.uk/Home/fs/en ). In: DOH, 2004.
26. British Medical Association. British National Formulary (BNF), No. 49. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, March 2005.